The latest study used HLA-unrestricted NY-ESO-1 vaccine combined with Decitabine to treat HR-MDS patients, and all patients showed NY-ESO-1 gene expression and induced NY-ESO-1 specific CD4+ and CD8+T cells (120). Here, CD4 is linked to myelodysplastic syndrome.